Recruiting PHASE3 INTERVENTIONAL 2-arm NCT05855746

Colchicine Versus Placebo in Acute Myocarditis Patients (ARGO)

Colchicine Versus Placebo in Acute Myocarditis Patients to Reduce Late Gadolinium Enhancement Mass on Cardiac Magnetic Resonance and the Risk of Clinical Outcomes: The ARGO Trial

Sponsor: Assistance Publique - Hôpitaux de Paris

Conditions Acute Myocarditis

Interventions Colchicine Pill Placebo

Updated 8 times since 2023 Last updated: Feb 23, 2026 Started: Jul 16, 2024 Primary completion: Jan 16, 2028 Completion: Jul 16, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Acute Myocarditis, this trial is actively recruiting participants. The trial is conducted by Assistance Publique - Hôpitaux de Paris and has accumulated 8 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE3
Feb 2025 — Feb 2026 [monthly]

Recruiting PHASE3
Sep 2024 — Feb 2025 [monthly]

Recruiting PHASE3
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Jul 2024 — Aug 2024 [monthly]

Not Yet Recruiting PHASE3

▶ Show 3 earlier versions

Jun 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE3
Dec 2023 — Jun 2024 [monthly]

Not Yet Recruiting PHASE3
Jun 2023 — Dec 2023 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Assistance Publique - Hôpitaux de Paris
Fonds de Dotation ACTION
Hospices Civils de Lyon

Data source: Assistance Publique - Hôpitaux de Paris

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bron, France
• Paris, France